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Abstract β-cells, located in the islets of the pancreas, are re-
sponsible for production and secretion of insulin and play a
crucial role in blood sugar regulation. Pathologic β-cells often
cause serious medical conditions affecting blood glucose level,
which severely impact life quality and are life-threatening if
untreated.With 347million patients, diabetes is one of the most
prevalent diseases, and will continue to be one of the largest
socioeconomic challenges in the future. The diagnosis still re-
lies mainly on indirect methods like blood sugarmeasurements.
A non-invasive diagnostic imaging modality would allow di-
rect evaluation of β-cell mass and would be a huge step to-
wards personalized medicine. Hyperinsulinism is another seri-
ous condition caused byβ-cells that excessively secrete insulin,
like for instance β-cell hyperplasia and insulinomas. Treatment
options with drugs are normally not curative, whereas curative
procedures usually consist of the resection of affected regions
for which, however, an exact localization of the foci is neces-
sary. In this review, we describe potential tracers under devel-
opment for targeting β-cells with focus on radiotracers for PET
and SPECT imaging, which allow the non-invasive visualiza-
tion of β-cells. We discuss either the advantages or limitations
for the various tracers and modalities. This article concludes
with an outlook on future developments and discuss the poten-
tial of new imaging probes including dual probes that utilize
functionalities for both a radioactive and optical moiety as well
as for theranostic applications.
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Why is non-invasive β-cell imaging necessary?
The islets of Langerhans, dispersed all over the pancreas
with the highest density in the tail, consist of different
specialized cells: α-cells, responsible for the production
of glucagon, δ-cells producing somatostatin, PP cells and
ε-cells that secrete ghrelin. β-cells, making up to 65–80%
of the cells in the islets, are involved in the control of blood
glucose levels through insulin secretion [1–3]. Pathologic
conditions disturb insulin secretion and lead to a blood
glucose imbalance that strongly impairs quality of life
and is potentially fatal if not treated. Hyperglycemia,
which can result from insufficient insulin response, leads
to long-term vascular damage and, in acute instances, can
lead to life-threatening ketoacidosis [4]. Hypoglycemia, in
contrast, can cause a critical lack of glucose in the brain,
potentially resulting in cerebral damage or, in acute cases,
neuroglycopenic symptoms and death [5]. The most prom-
inent cause for hyperglycemia is diabetes, one of the most
prevalent diseases of our time. It already affects more than
347 million people worldwide and the incidence continu-
ously grows at an alarming rate [6]. Diabetes can be divid-
ed into two types. Type 1 diabetes is caused by an autoim-
mune reaction towards β-cells, resulting in a lack of insu-
lin secretion, leading to hyperglycemia [7]. Type 2 diabe-
tes, in contrast, is a chronic metabolic disease. In this case,
the hyperglycemia is caused by the desensitization of the
insulin receptors on different cell types, mainly in liver,
muscle, and fatty tissue [8]. Initially, the β-cells can com-
pensate for the lack of insulin response by an elevated
insulin secretion level which, however, cannot be
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maintained in the long run and ultimately β-cells lose their
function in response to factors like dedifferentiation or ap-
optosis [9, 10]. Since data about pathologic β-cells can
only be obtained post mortem, a lot of the pathogenesis
of diabetes is still under debate [1]. Currently, the standard
diagnostic tests of both type 1 and 2 diabetes determine
only indirectly if the patient is persistently hyperglycemic
by analyzing either plasma glucose or glycated hemoglo-
bin levels (HbA1c). However, these markers change only
after more than 80% of the β-cells lost function. Thus,
other alternatives are needed to monitor changes in β-cell
function and mass [11].
Non-invasive β-cell imaging would allow following the
pathogenesis of diabetes and might give more insight into the
disease progression and β-cell mass as the disease develops.
This could also eventually lead to a more efficient diagnostic
method allowing physicians to tailor the treatment to the patient
and to intervene before the loss of β-cell mass is irreversible.
Additionally, β-cell imaging might allow in vivo tracking of
transplanted islets, which in the future might be a prognostic
tool to define treatment strategies for transplanted type 1 dia-
betes patients. Transplanted islets, focally engrafted into the
brachioradialis muscle, were successfully labeled utilizing a
radiolabeled GLP-1R agonist. Both the right transplantation
and imaging protocols, however, have to be considered. A
commonly used technique is the injection of the isolated islets
into the portal vein, leading to the engraftment into the liver, as
this results in a diffuse localization of the islets situated within
an organ that non-specifically accumulates many tracers mak-
ing a visualization very challenging [12–14].
Hypoglycemia, on the other hand, is a condition that can be
caused by pathologic β-cells, which secrete an excess of in-
sulin. The goal of the treatment of all kinds of hyperinsulinism
is to reach normoglycemia. The standard treatment for
insulinomas, the main reason for hyperinsulinism in adults,
is resection. Treatment with drugs will be only performed if
surgery is not an option for medical reasons. Non-invasive
imaging of cancer cells, in contrast, allows the physician a
precise assessment of the situation and specific excision of
the affected tissue and therefore minimizes potential future
complications.
The first-line approach for patients with congenital hyper-
insulinism is medical therapy with diazoxide and later on with
octreotide. Surgery is a second-line therapy if the medical
application fails due to side effects or not responding, and if
a focused lesion could be localized [15–17]. As both those
foci as well as healthy β-cells are usually quite small, howev-
er, an imaging modality with both high sensitivity and resolu-
tion is required [18].
The majority of adult beta cell hyperplasia are non-focal
hyperplastic manifestations and can be kept under control in
most of the cases with medical treatment. Therefore, imaging
may play a minor role in such patients.
This review gives a short overview of the various imaging
modalities suitable for β-cell imaging. Techniques not offer-
ing a sufficient sensitivity or resolution to visualize pancreatic
β-cells, such as computed tomography (CT) or diagnostic
sonography, were omitted. Further, potential targets and
probes that are currently being investigated as tracers for β-
cell imaging are discussed with a special focus on radiotracers
for positron emission tomography (PET) and single-photon
emission computed tomography (SPECT). An overview of
the possible targets is shown in Fig. 1 and Tables 1, 2.
Non-invasive imaging modalities used for β-cell
visualization
As β-cell islets are relatively small and occupy a minor portion
of the pancreas, their imaging is challenging. Potential imaging
modalities require certain properties, such as high sensitivity
and spatial resolution, which limits the feasible choices. This
chapter discusses the potential modalities and their properties
and evaluates their advantages and shortcomings.
Fig. 1 An overview of the most promising targets and imaging
modalities reviewed in this article
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Magnetic resonance imaging (MRI)
MRI uses strong oscillating magnetic fields to excite hydrogen
atoms, mostly in tissues containing water molecules. Excited
hydrogen atoms emit radio frequency signals that can be detected
by a receiver and transformed into an image. As different tissues
have a distinctive rate with which the excited hydrogen atoms
return into the relaxed state, most anatomical structures can be
clearly distinguished with a very high resolution. Sensitivity of
MRI, however, is significantly lower compared to SPECT or
PET, a concentration in the low micromolar range is necessary
for detection [74–76]. Different contrast agents can be used to
more clearly visualize specific tissues, the most common ones
being gadolinium, iron oxide, and manganese [77].
Single-photon emission computed tomography (SPECT)
The principle of SPECT is the administration of a γ-ray-
emitting radiotracer. The signal is detected by rotating detec-
tors registering the radioactive decay of the tracer in the
subject’s body and can be reconstructed into a three-
dimensional image. As the γ-emission is random and only
the signal perpendicular to the detector is desired, a major
fraction of the signal has to be filtered by collimators.
Compared to most other imaging techniques, however,
SPECT offers a high sensitivity in the picomolar range [75,
76, 78]. Commonly used radionuclides for SPECT are 99mTc,
111In, 123I, and 131I [79]. One additional point that has to be
taken into account is that only 1–2% of the pancreas are β-
cells, meaning that the number of targets is limited. In conse-
quence, the specific activity of the tracers targeting structures
with limited quantities, like for instance β-cell receptors, is
necessary to avoid saturation of the targets with non-active
tracer, resulting in a strongly reduced signal [49]. Another
minor challenge of SPECT imaging is the partial volume ef-
fect, which occurs if the signal originates from structures
smaller than the resolution of the modality. This can lead to
the underestimation of the signal and influences the quantifi-
cation of β-cell mass (BCM). However, further analysis is
required to determine to which extent the signal is affected.
Table 1 Advantages and
disadvantages of the different







PET + − + 11C, 18F, 68Ga, 64Cu
SPECT + − + 99mTc, 111In, 123I, 131I
MRI − + + SPIO, Gd3+, Mn2+
Optical imaging + + − Luciferin, NIR fluorophores
Table 2 Summary of the tracer discussed in this review with the corresponding targets as well as their current status
Target Imaging agent Current status References
VMAT2 [11C]DTBZ Preclinical studies (in vitro and in vivo in rats) [19]
[18F]FE-DTBZ d4 Preclinical studies (in vitro and in vivo in pigs) [20]
[18F]-FP-(+)-DTBZ Clinical studies [21–23]
SUR1 18F and 99mTc labeled glibenclamide derivatives Clinical studies [24]
99mTc-DTPA-glipizide Preclinical studies (in vitro and in vivo in mice) [25]
Sphingomyelin patches on
the β-cell surface
111In-DTPA-IC2 Preclinical studies (in vitro and in vivo in mice) [26, 27]
β-cell-surface epitopes 125I-labeled SCA B1, SCA B2, SCA B3, and
SCA B4; SCA B2 functionalized carbon-coated
cobalt NP
Preclinical studies (in vitro and in vivo in mice
and rats)
[28, 29]
hTMEM27 AF 488 / [89Zr]-8/9-mAb Preclinical studies (in vitro and in vivo in mice) [30]
Glucose transporter 18F-FDG, Clinical studies [31, 32]
LAT 18F-DOPA, [11C]-5-HTP Clinical studies [33–37]
D2 receptor [18F]-fallypride Preclinical studies (in vitro and in vivo in rats) [38–40]
Zn2+release GdDOTA-diBPEN Preclinical studies (in vitro and in vivo in mice) [41–43]
Voltage-gated Ca2+ Ca2+
channels
Mn2+ Preclinical studies (in vitro and in vivo in mice),
retrospective study in humans
[44–47]
Unclear PiY Preclinical studies (in vitro and ex vivo analysis
of mouse organs)
[48]
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Positron emission tomography (PET)
PET, another nuclear imaging technique, detects the γ-rays
resulting from the annihilation of a positron emitted from the
radionuclide embedded in a tracer molecule. After collision
with an electron, the resulting annihilation produces two pho-
tons that are emitted in a 180° angle and are detected by a
detector ring. Events are only registered if they are a coinci-
dence in an angle of 180°, eliminating the necessity for colli-
mators and resulting in even higher sensitivity than SPECT in
the femto- to picomolar range [76]. The time difference be-
tween the detection of the two photons allows an exact spatial
localization of the disintegration permitting a three-
dimensional reconstruction of the signal (time of flight;
TOF) [80]. The most common radionuclide is 18F. Its physical
and chemical features such as the low energy and high yield of
the emitted β+ as well as the fact that it is a bioisostere of
oxygen, allow easy replacement of hydroxyl groups.
Therefore, it only slightly affects the properties of the mole-
cule. Other frequently used PET nuclides are 11C, 68Ga, and
64Cu [81–83]. As for SPECT imaging, tracer aimed at β-cell-
specific targets need to have a high specific activity. PET
imaging also suffers from the partial volume effect.
Optical imaging
Optical imaging is a growing field in preclinical and clinical
applications. Different methods were developed including
bioluminescence tomography (BLT), fluorescence molecular
tomography (FMT), and optical projection tomography
(OPT), which are described in detail in the review of
Rzansky et al. [84]. Optical imaging in general describes the
detection of light of a particular wavelength. Fluorescent pro-
teins have been used for a long time to track cells and proteins
in vitro. More recently, this technology has been applied for
in vivo imaging in animals. The signal can be either generated
by bioluminescence, where the optical moiety has to be acti-
vated in vivo by an enzyme, usually luciferase, which was
transfected in the target tissue [85]. Fluorescent probes on
the other hand contain an optical moiety that, after excitation
at a specific wavelength, emits a signal of a different wave-
length [86, 87]. In both cases, the optical signal with the de-
fined wavelength can be detected with both a high spatial
resolution and high sensitivity. Depending on the wavelength,
the fluorescent signal is easily scattered. Thus, the imaging of
organs is still challenging. A large variety of fluorophores are
available, ranging from low wavelengths such as 510 nm
(green fluorescence protein), which are not suitable for
in vivo imaging, up to 900 nm (near-infrared flourophores),
providing a better penetration for imaging of deeper tissues
[86]. Such near-infrared (NIR) probes are successfully used
for intraoperative detection of various lesions [88–90].
Possible targets for radiotracers for β-cell imaging
VMAT2
The vesicular monoamine transporter 2 (VMAT2), an integral
membrane protein responsible for the transport of neurotrans-
mitters, is widely expressed in the central and peripheral ner-
vous system but also in the hematopoietic and neuroendocrine
systems. As an integral part of the neuroendocrine system,
pancreatic β-cells express VMAT2, which is a promising tar-
get for PET/SPECT radiotracers [89, 91, 92]. So far, all studies
have been performed with derivatives of dihydrotetrabenazine
(DTBZ), the most prominent ones is [11C]DTBZ (Fig. 2)
which was originally a tracer for diagnosis of patients suffer-
ing from Parkinson’s disease. [18F]fluoroethyl [FE]-DTBZ
and the metabolically more stable deuterated analogue
[18F]FE-DTBZ d4 are further promising analogues [19–21,
41–43, 93].
The applicability of these tracers, however, is under debate.
According to Fagerholm et al., the highest activity after injec-
tion of [11C]DTBZwas found in the pancreas, yet the majority
of the signal was not found in the islets but as non-specific
binding to the exocrine pancreas as well as to PP cells in both
human and rat samples. Similar findings were reported for
[18F]FE-DTBZ in addition to a high metabolic defluorination,
which led to a high 18F accumulation into the bones. The high
uptake in PP cells and delta cells may be related to the expres-
sion of VMAT2 in these cells compared to β-cells [19, 21,
44–47]. Jahan et al. resolved the latter problem by the substi-
tution of four ethyl hydrogens of [18F]FE-(+)-DTBZ to deu-
terium, resulting in the compound [18F]FE-(+)-DTBZ d4.
However, the exocrine-to-islet ratio remained the same, lead-
ing to the conclusion that BCM determination might not be
feasible, but the tracer might be used for studying focal clus-
ters of β-cells, as in the case of intramuscular transplantation
[20, 48]. In addition, Normandin et al. reported quantifiable
changes in BCM of type 1 diabetic patients, which is not
observed in healthy humans after the administration of 18F-
FP-(+)-DTBZ. Furthermore, the non-specific binding was not
determined, and it is not clear if BCM might have been
Fig. 2 Structure of 11C-(+)-DTBZ as an example for VMAT2 tracer
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overestimated [22, 49–51]. A study in baboons, performed by
Harris et al., tried to quantify the non-specific binding in the
pancreas using 18F-FP-(−)-DTBZ, the negative enantiomer
that does not bind to VMAT2. Subtracted from the binding
of 18F-FP-(+)-DTBZ, it should give the specific β-cell related
signal. Even though the results are promising, some critical
factors remain. First, the non-specific binding in diabetic pa-
tients was higher due to persistent inflammatory changes.
Secondly, δ and PP cells can also express VMAT2 adding to
β-cell signals. Thus, these two factors contribute to the over-
estimation of BCM in patients with type 1 diabetes [23, 52,
89].
An additional important point regarding targeting VMAT2
is the appropriate animal model. Many in vivo studies were
performed in rodent models [19, 43, 53, 93, 94]. However,
Schäfer et al. showed that rodent species do not express
VMAT2 in β-cells. The observed uptake in the pancreas
may be caused by binding to VMAT2 expressed in sympa-
thetic nerve terminals that innervate the islets and mast cells.
Models suitable forβ-cell-specific VMAT2 imaging would be
non-human primates and pigs, as they show similarly high
VMAT2 expression as humans [43, 95].
In conclusion, VMAT2 might be a useful target for β-cell
imaging. Current tracers still display a high unspecific uptake,
mainly in the exocrine pancreas, which has to be further opti-
mized. In addition, it is important to apply an appropriate
in vivo model as rodents do not express VMAT2 in the islets.
SUR1
The sulfonylurea receptor 1 (SUR1) is a subunit of ATP-
dependent potassium channels (KATP), which are involved
in the insulin secretion from β-cells. While different iso-
forms of SUR exist, SUR1 is specifically found on β-cells
and in the brain. Sulfonylureas like tolbutamide,
glibenclamide, and glipizide, are widely used drugs for
the management of type 2 diabetes [33, 49–51, 54, 96].
So far, a few radiolabeled SUR1 derivatives have been
tested as potential candidates for β-cell imaging.
Schneider et al. investigated various 18F and 99mTc labeled
glibenclamide derivatives. Although good binding affinity
to the receptor as well as pharmacological effects were
observed, an imaging study in humans was not successful.
A stable radioactive signal was detected in the pancreas,
however, a high background hindered reliable quantifica-
tion [24, 55]. 99mTc-DTPA-glipizide (Fig. 3), another sul-
fonylurea derivative assessed by Oh et al., was tested in
mice. Due to its higher hydrophilicity, the main accumu-
lation of the tracer changed from liver and intestine to the
kidneys. Even though a persistent accumulation in the
pancreas was detectable, the specific signal was still very
low in comparison to the background [25, 56].
Currently, none of the available probes targeting SUR1 are
feasible forβ-cell imaging. Thus, further studies are necessary
to improve SUR1-targeting traces.
Other β-cell-surface epitopes
Various antibodies aimed at β-cell-specific epitopes have re-
cently been tested. IC2, an antibody directed against
sphingomyelin patches present on the β-cell surface, is one
potential tracer that could be utilized for imaging β-cells. So
far, it was shown that the antibody specifically binds to both
human and murine β-cells and that the uptake of 111In-DTPA-
IC2 correlates with β-cell mass in healthy and diabetic mice
[26, 57, 97]. In another study, Ueberberg et al. used a phage
library to generate highly specific single-chain antibodies
against human β-cells. After administration of 125I-labeled
antibody, the pancreatic uptake of the tracer with BCM corre-
lates, but more extensive in vitro and in vivo studies are need-
ed to fully assess the promising potential of those antibodies
[28, 58].
The transmembrane protein 27 (TMEM27), another poten-
tial antigen, is specifically expressed on the β-cell surface and
on kidney collecting ducts. Vats et al. characterized 8/9 mAb,
an antibody against the human variant of TMEM 27
(hTMEM27). They used both a fluorescent labeled and
radiolabeled construct to determine the uptake in tumor xeno-
grafts and islets of transgene mice. The tracers showed a high
and specific uptake into hTMEM27-positive tumors after
1 day. Uptake in pancreatic sections co-localized with insulin
Fig. 3 Structure of DTPA-glipizide, a tracer that can be used for the
visualization of SUR1
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staining, confirming the specificity for β-cells. Nevertheless,
the sensitivity of the antibody has to be improved as the ex-
pression of hTMEM27 was ten times lower in humans as
compared to the transgenic mice used in this study [30, 59].
These encouraging results for β-cell imaging with antibod-
ies requires further validation studies such as biodistribution
analysis and PET or SPECT scans in relevant animal models.
Furthermore, a potential disadvantage of using antibodies as
radiotracer includes long blood circulation time leading to a
longer exposure and potentially higher radiation burden.
Additionally, as they are highly lipophilic, most antibodies
accumulate in the liver, potentially adding to the background.
Radiolabeled saccharides and neurotransmitters
Tracers that are not specific for β-cells have also been used to
image various β-cell-related conditions. 18F-FDG, the most
prominent PET tracer, was successfully used to visualize
transplanted islets. A small fraction of the islets were labeled
ex vivo with 18F-FDG prior to intraportal transplantation and
mixed with the rest of the islets. Eriksson et al. were able to
assess the distribution of the transplanted islets in five patients
for an hour. The short half-life (110 min) of 18F, however,
limits its use for long-term studies [31, 49–51, 60].
A study performed by Malaisse et al. evaluated the uptake
of 18F-FDG in healthy and streptozotocin-induced diabetic
rats. In this study, they failed to see a lower accumulation in
the diabetic pancreas compared to the control, leading to the
conclusion that 18F-FDG is not suitable for the detection of
pancreatic β-cells [32, 61].
18F-L-dihydroxyphenylalanine (18F-DOPA), a metabolic
tracer like FDG, is taken up by the large amino acid
transporter (LAT) and metabolized to 18F-dopamine by the
DOPA decarboxylase trapping it in the cells. Since it taken
up in both exocrine and endocrine pancreatic cells, the poten-
tial use is limited. Still, patients suffering from hyperinsulin-
ism, either caused by insulinomas or β-cell hyperplasia, can
benefit from imaging with 18F-DOPA. Several groups have
reported successful imaging of those foci [34, 35, 62, 63]. A
report from Tessonier et al. in contrast reports an underestima-
tion of the extent the disease after 18F-DOPA imaging.
Nevertheless, it seems that the pancreas has high decarboxyl-
ase activity, leading to a high background [64–67, 98].
Imperiale et al. suggest pre-administration of carbidopa,
which lowers the pancreatic 18F-DOPA activity while preserv-
ing the signal in the foci (Fig. 4) [19, 33, 68–70]. [18F]-
fallypride, a dopamine D2-receptor antagonist, first synthe-
sized by Mukherjee et al., is commonly used as a PET brain
tracer [41, 99]. With the discovery that the D2-receptor is also
expressed in β-cell islets where it co-localizes with insulin
granules, however, it was suggested to use the receptor as a
target for β-cell imaging [38, 60]. Garcia et al. confirmed the
uptake in vivo. Imaging of the pancreas, though, proved to be
difficult. On the one hand, the uptake in the islets was signif-
icantly lower than in the brain; on the other hand, the unspe-
cific binding in the islets was approximately 50%.
Nonetheless, a significant reduction of the pancreatic uptake
was observed in streptozotocin-induced diabetic rats, which
correlated with the loss of the β-cells. Furthermore, Garcia
et al. were able to localize human islets pre-labeled with
[18F]-fallypride, 1.5 h after transplantation using PET [39,
40, 71].
[11C]-5-Hydroxytryptophane ([11C]-5-HTP), originally a
tracer to determine serotonin biosynthesis in various tissues
Fig. 4 Carbidopa-assisted 18F-
DOPA PET of a patient suffering
from insulinoma. The arrow
clearly indicates the lesion. a
Early PET acquisition. b Axial
PET/CT fusion. c Delayed PET
acquisition. d Contrast-enhanced
ultrasonography [33]
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is nowadays clinically used to diagnose neuroendocrine tumors
like insulinoma. Similarly to previous tracers, [11C]-5-HTP is
taken up by the large amino acid transporter (LAT) and specif-
ically metabolized by the DOPA decarboxylase to [11C]-sero-
tonin, which is trapped intracellularly. Various studies have
shown that the islets of Langerhans, particularly the granules
of the β-cells, specifically accumulate serotonin, making [11C]-
5-HTP a potential tracer to image β-cells [42, 100, 101]. Even
though [11C]-5-HTP also accumulates in other endocrine islet
cells, Ericsson et al. were able to distinguish between healthy
and type 1 diabetic patients as the tracer accumulation was
strongly reduced [36]. Di Gialleonardo et al. in contrast were
not able to differentiate between endocrine and exocrine pan-
creas, however, as they only performed in vitro assays on cell
lines, additional experiments would be necessary to test this
hypothesis in vivo [28, 29, 37, 68, 70]. Overall, [11C]-5-HTP
seems to be a promising tracer, especially for imaging
insulinomas and transplanted islets. However, it will not be able
to distinguish between healthy subjects and subjects with dia-
betes due to a too large overlap between the groups.
GLP-1 receptor
The glucagon-like peptide 1 receptor (GLP-1R), expressed in
β-cells, stimulates insulin synthesis and secretion as well as
promotes β-cell proliferation. As it is specifically expressed
on β-cells, it is a viable target for imaging [73, 102–107]. The
endogenous peptide GLP-1, however, has a very short plasma
half-life, as it is rapidly metabolized by dipeptidyl peptidase-4
(DPP4), making it unsuitable as a tracer [33, 108]. Exendin-4,
in contrast, a peptide first isolated from the saliva of
Heloderma suspectum, is highly stable in vivo while having
the same high affinity to the receptor as GLP-1 and induces
the insulin secretion as well [47, 103, 107]. Due to the high
affinity and efficacy synthetic exendin-4, known as exenatide,
is successfully used for the treatment of type 2 diabetes. These
pharmacological properties qualify exendin-4 as a lead com-
pound for the tracer development for β-cell imaging, such as
the C-terminally modified peptide (Fig. 5). Gotthardt et al.
showed that 111In-DTPA-Lys40-exendin-4, a radiolabeled de-
rivative of exendin-4, specifically binds to GLP-1R-positive
tissues in rats. In addition, they were able to successfully im-
age those structures with SPECT, concluding that this imaging
technique might be used to examine both healthy GLP-1R-
expressing tissue as well as tumors [64, 70]. Wild et al. con-
firmed this hypothesis using the same exendin-4 derivative in
Rip1Tag2 transgenic mice with spontaneous insulinoma
showing exceptionally high uptake in the tumors [50].
Recent studies in human patients confirmed the potential for
the pre- and intraoperative detection of insulinomas (Fig. 6).
The results indicate an improvement compared to currently
used diagnostic methods for non-malignant insulinomas, as
it is more sensitive than CT/MRI. The authors examined three
patients withβ-cell hyperplasia during this study and conclud-
ed that the detection of β-cell hyperplasia with radiolabeled
exendin may be insufficient because the large interindividual
variation of β-cells [51, 52]. Further studies to clarify the
value of GLP-1 receptor imaging in patients with β-cell hy-
perplasia are necessary.
To date, various exendin derivatives have been tested with
the goal of either utilizing different nuclides or changing the
pharmacological properties. [Lys40 (Ahx-HYNIC-99mTc/
EDDA)NH2]-exendin-4, another SPECT tracer utilizing the
widely available 99mTc, also successfully visualized
insulinomas in vivo with the added benefit regarding the esti-
mated effective dose, which was 40 times lower as compared
to 111In labeled lead compound. A first in man study con-
firmed the usefulness of this tracer in imaging benign
insulinoma foci in patients [43, 53]. [Lys40(Ahx-
DOTA-68Ga)NH2]-exendin-4 on the other hand proved to be
a potential alternative to [Lys40(Ahx-DTPA-111In)NH2]-
exendin-4 for PET imaging, potentially allowing the localiza-
tion of smaller insulinomas due to the superior resolution of
PET while retaining the pharmacokinetics. In addition, the
radiation burden of 68Ga is also lower than for the 111In, min-
imizing the dose for the patients [43]. Selvaraju et al.
Fig. 5 Structure of Ex4NOD40
as an example of radiolabeled
exendin-4 derivatives. The moie-
ties in red have been attached to
the C-terminal end of the peptide
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performed a study with a similar peptide, 68Ga-DO3A-
exendin-4 in rats as well as in non-human primates. The dif-
ference of tracer uptake in the pancreas after streptozotocin-
induced destruction ofβ-cells was observed, suggesting that a
non-invasive quantification of GLP-1R is feasible [54]. A
comparison between 68Ga and 64Cu revealed that
[64Cu]NODAGA-exendin-4 shows a higher specific uptake
in GLP-1R-expressing tissue than the 68Ga-labeled peptide
in rats. PET imaging, however, failed to visualize the pancre-
as. Kirsi et al. concluded that the high radiation burden due to
the high kidney uptake limits the feasibility of the 64Cu-la-
beled peptide as a clinical tracer [56]. Another 64Cu-labeled
peptide, DO3A-VS-Cys40-exendin-4 tested by Wu et al.
strongly accumulated in INS-1-grafted tumors in NOD/
SCID mice and successfully visualized transplanted islets
[55].
Two 18F exendin-4-based tracer [18F]FBEM-[Cysx]-
exendin-4, derivatized either at the C-or N-terminal end of
the peptide, tested by Kieswetter et al., showed high tumor
uptake where the C-terminally modified derivative seemed to
have a superior tumor uptake and tumor-to-background ratio.
18F-TTCO-Cys40-exendin-4 and 18F-FBEM–Cys39-exendin-
4, two similar derivatives tested by Wu et al. and Xu et al.,
respectively, showed comparable results [57, 58]. Other 18F-
labeled tracers were either modified on the lysine in position
12 (18F-E4Tz12) or position 27 ([
18F]Ex(9–39)) and modified
18F-E4Tz12 shows similar distribution as original peptides,. A
comparison of PET images between diabetic and non-diabetic
rats did not yield any difference [59, 109]. Nevertheless, the
question remains if this method is sensitive enough.
A disadvantage of covalently bound 18F tracers is the com-
plicated and time-consuming labeling process of those pep-
tides. In contrary [18F]AlF-NOTA-MAL-cys40-exendin-4 can
be easily synthesized and retains the high uptake in GLP-1R
expressing tissue. Unfortunately, the kidney uptake of
[18F]AlF-NOTA-MAL-cys40-exendin-4 is much higher than
the peptides with covalently bound 18F [61].
Studies with exendin-4(9–39) derivatives, which are GLP-
1R antagonists can also potentially be used to image β-cells.
Brom et al., however, conclude that agonists are more favor-
able, as they accumulate stronger in the tumor, most probably
because of the higher internalization of the agonist. Waser
et al., in contrast, suggest that for insulinoma, antagonists
might be favorable, as they do not induce a transient hypogly-
cemic effect as opposed to GLP-1R agonists [63, 66, 109].
A study by Jodal et al. investigated the influence on differ-
ent potential conjugation sites of exendin-4 labeled with 67/
68Ga, concluding that the lysines in position 12 and 40 have
the least influence on the biological properties of the peptides.
The lysine in position 27, though, is also potentially modifi-
able without losing too much affinity, which is in contrast to
findings ofWang et al. who did not see any remaining specific
binding of 18F-labeled exendin-4(9–39) conjugated to Lys 27,
leading to the conclusion that depending on the modification,
the binding to the receptor might be impaired.
Another peptide tested by Brom et al. is exendin-3, which
differs in only two amino acids from exendin-4. Lys40(68Ga-
DOTA)] exendin-3 successfully visualized INS-1 tumor xe-
nografts in BALB/c nude mice. 111In labeled Lys40(DTPA)]-
exendin-3 showed comparable biodistribution to the corre-
sponding exendin-4 derivative. This peptide was successfully
used to quantify BCM in rats. However, studies in humans
confirmed high interindividual differences in BCM, which is
in line with previous reports. Nevertheless, pancreatic uptake
of the tracer in diabetic patients was reduced as compared to
healthy subjects, indicating that this might be a feasible tech-
nique for BCM quantification in humans [66, 67].
Recently, 125I-labeled liraglutide, a stabilized derivative of
the natural ligand GLP-1, was assessed as a probe. The bind-
ing affinity of the peptide was lower than for previously tested
exendin derivatives and even though INS-1 tumors were vi-
sualized in a xenograft mouse model, background activity was
very high with much of the activity accumulating in non-GLP-
1-positive organs like liver, thyroids, and salivary glands [41].
Therapeutic studies revealed that application of up to
28 MBq [Lys40(Ahx-DTPA111In)NH2]-exendin-4 leads to a
significant reduction of the tumor size of up to 94%, while
healthy β-cells were not affected. One issue, however, is a
high, non-GLP-1R-mediated uptake in the kidneys, resulting
Fig. 6 Coronal (a) and transaxial (b) SPECT/CT images from a patient
with biochemically proven hyperinsulinemic hypoglycemia 72 h after the
injection of 85 MBq 111In-DOTA-exendin-4. There is focal uptake of
111In-DOTA-exendin-4 in the pancreatic tail (arrow) consistent with the
surgically removed and histological proven insulinoma
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in morphological changes after the administration of 28 MBq
tracer. This limits the applicability of Lys40(Ahx-
DTPA111In)NH2]-exendin-4 as a therapeutic agent [49]. The
same observation was made by Velikyan et al. for the therapy
with 177Lu-labeled DO3A-VS-Cys(40)-exendin-4 [110]. A
high kidney uptake is a common issue with exendin deriva-
tives, not just because of the radiation burden but also the high
background, which might hamper the detection of a specific
signal in close proximity to the kidneys. The latter is especial-
ly an issue for the imaging of non-hyperplastic tissues, as the
uptake is less concentrated, leading to a lower signal intensity
[53, 56, 69]. Various attempts have been made to reduce the
kidney accumulation. One clinically applied method is the
pre-administration of amino acids. Gotthardt et al. applied this
method for exendin and tested the kidney uptake after the
administration of lysine, gelofusine, polyglutamic acid, or
the combination of gelofusine and polyglutamic acid. While
the administration of lysine did not have any affect, both
gelofusine and polyglutamic acid as well as the combination
of both had an significant impact on the uptake of exendin in
the kidneys [111]. A different approach to reduce kidney up-
take is the introduction of a cleavable linker before the
radiolabeled moiety of the peptide. This linker should be spe-
cifically cleaved at the kidney brush-border membrane, liber-
ating the radioactive moiety as a small fragment that can be
easily excreted in the urine. An Nε-maleoyl-L-lysine linker,
cleaved by various peptidases on the brush-border membrane
of kidney proximal tubule cells has been successfully used to
reduce kidney uptake of fab fragments [112]. Yim et al.
adapted this linker for exendin-4, however, the kidney uptake
of [64Cu]NODAGA-MAL-exendin-4 was not improved com-
pared to the reference substance [60]. Another peptidase that
could be potentially used to specifically cleave linker se-
quences is meprin β. Jodal et al. designed three exendin-4
derivatives containing liner sequences specific for meprin β.
While those linkers were cleaved in vitro, they did not manage
to reduce the kidney uptake in vivo [71].
These results show that the GLP-1R is a very promising
target for the assessment of β-cells and can be utilized for
different purposes. Many different exendin derivatives have
been tested so far, proving the versatility of this peptide and
making it the most viable option for GLP-1R targeting up to
now. One remaining challenge, however, is the high kidney
accumulation, which potentially can lead to a high radiation
burden for the patient.
β-cell visualization with MRI and optical imaging
Magnetic resonance imaging (MRI)
As β-cells and insulinoma are small structures, a modality
with high spatial resolution would be ideal to visualize
individual islets or clearly defined foci. Utilizing the superior
spatial resolution of MRI, Balla et al. successfully managed to
image single islets, both ex vivo and in vivo using carbon-
coated ferromagnetic cobalt nanoparticles functionalized with
a β-cell-specific single-chain antibody as a contrast agent.
Nevertheless, some issues remain unsolved. On the one hand,
it unspecifically accumulated in liver and spleen, which is a
common problem for most nanoparticles. On the other hand,
potential cytotoxic effects of the nanoparticles have to be in-
vestigated before studies in humans can be conducted [29].
Various functionalized and unfunctionalized nanoparticles
have been tested so far (Table 3), most of them, however, only
to label transplanted islets [113–116]. Wang et al. and Vinet
et al. both assessed nanoparticles that have been functional-
ized with exendin-4 targeting GLP-1R in mice. Both report a
significant reduction of the contrast agent in diabetic mice
compared to uptake in healthy controls, concluding that they
might be of use in monitoring the development of diabetes
[72, 117]. Long-term toxicity studies of nanoparticles, how-
ever, are still missing, and have to be performed before a
clinical application.
A different approach utilizes the fact that insulin is stored in
combination with Zn2+ in vivo, meaning that the extracellular
concentration of Zn2+increases after the glucose-dependant
release of insulin. After administration of the Zn2+-responsive
contrast agent GdDOTA-diBPEN, Lubag et al. were able to
detect a pancreatic signal specifically in healthy mice after
administering glucose. In both streptozotocin-induced diabet-
ic mice and healthy controls that did not receive glucose, no
pancreas signal was detected. An increased uptake was found
in mice that were on a high-fat diet for an extended period.
This is consistent with previous reports on increased insulin
secretion in obese, insulin-resistant patients [42].
Nevertheless, more studies are necessary to see if it is possible
to differentiate between the change in BCM and β-cell
function.
Many studies have been published on manganese as a con-
trast agent for β-cell imaging. Mn2+ is a Ca2+ analogue that
can enter β-cells trough voltage-gated Ca2+ channels,
resulting in a specific, glucose-dependant signal [45, 118].
Administering 47 mg/kg of MnCl2 as a contrast agent,
Lamprianou et al. were able to visualize single islets up to
the size of 50 μm both ex vivo and in vivo, proving the fea-
sibility of Mn2+ as a contrast agent for imaging native β-cells
[44]. Antkowiak et al. were able to observe a gradual decrease
of Mn2+ accumulation after cyclophosphamide-induced β-
cell apoptosis, even before diabetic symptoms occurred, indi-
cating the potential as a diagnostic tool for the early diagnosis
of diabetes [45]. Dhyani et al. hypothesized that autoimmune
damage to β-cells as well as changes in the microvasculature
can predict the development of type 1 diabetes. Using Mn2+-
enhanced dynamic MRI and an empirical mathematical mod-
el, they were able to observe different uptake in head, body,
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and tail of the pancreas in both healthy and diabetic mice.
Following this data, they were able to link changes in β-cell
and perfusion to functional transformations in the pathogene-
sis of diabetes, concluding that those parameters might be
used as potential biomarkers for the diagnosis of diabetes
[46]. A retrospective study by Bostikas et al. compiled the
existing data from previous Mn2+-enhanced MRI data and
assessed uptake in pancreas of both non-diabetic and type 2
diabetic patients, as indicated in Fig. 7. In both cases, the MRI
signal was enhanced, however, the extent of the enhancement
significantly correlated with the BMI of the patients but not
other factors like age or insulin requirement. As this was a
retrospective study, the number of patients was limited, and
the images taken were not optimized for imaging the pancreas.
It would be interesting to see if further studies in healthy and
diabetic patients can confirm this data [47]. In summary, these
results lead to the conclusion that Mn2+ might be suitable for
the longitudinal imaging of β-cell mass and function, howev-
er, further studies in humans are necessary. In addition, toxic-
ity ofMn2+ has to be investigatedmore closely before it can be
routinely used in humans.
Optical imaging
Optical imaging combines both a very high spatial resolution
(which can be high enough to image single cells) and a high
sensitivity, making it a very valuable imaging modality. The
first selective fluorescent probe targeting β-cells in vivo was
developed in 2010 by Reiner et al. This first-generation fluo-
rescent tracer was based on exendin-4 and targeted the GLP-
1R. The fluorophore VT680 attached to K12 of exendin-4
bound to the receptor with high affinity and successfully im-
aged in a proof-of-concept study single islets in mice with
intravital confocal microscopy demonstrating a quick and
Table 3 Summary of the GLP-1R-specific tracer reviewed in this article and their current status
Tracer Current status References
[Lys40(Ahx-DTPA111In)NH2]-exendin-4 Clinical studies [49–51]
Lys40(Ahx-111In-DOTA)NH2 exendin-4 Clinical studies [52]
[Lys40 (Ahx-HYNIC-99mTc/EDDA)NH2]-exendin-4 Clinical studies [43, 53]
[Lys40(Ahx-DOTA-68Ga)NH2]-exendin-4 Preclinical studies (in vitro and in vivo in mice) [43]
68Ga-DO3A-Exendin-4 Preclinical studies (in vivo in mice and non-human primates) [33, 49–51, 54]
64Cu-DO3A-VS-Cys40-exendin-4 Preclinical studies (in vitro and in vivo in mice) [55]
64Cu/ 68Ga-[Nle14,Lys40(Ahx-NODAGA)NH2]-exendin-4 Preclinical studies (in vitro and in vivo in rats) [56]
[18F]FBEM-[Cysx]-exendin-4 Preclinical studies (in vitro and in vivo in mice) [57]
18F-TTCO-Cys40-exendin-4 Preclinical studies (in vitro and in vivo in mice) [58]
18F-E4Tz12 Preclinical studies (in vitro and in vivo in mice) [59]
[18F]Ex(9–39) Preclinical studies (in vitro and in vivo in rats) [49–51, 60]
[18F]AlF-NOTA-MAL-cys40-exendin-4 Preclinical studies (in vitro and in vivo in mice) [61].
125I-GLP-1(7–36),
125I-BH-exendin(9–39)
Preclinical studies (in vitro and ex vivo in autoradiography
in mouse and human tissue)
[62, 63]








Preclinical studies (in vitro and in vivo in mice) [68–70]
125I -Liraglutide Preclinical studies (in vitro and in vivo in mice) [41]
[64Cu]NODAGA-MAL-exendin-4 Preclinical studies (in vitro and in vivo in rats) [60]
111In-PSI-CLNOD1 Preclinical studies (in vitro and in vivo in mice) [71]
111In-PSI-CLNOD2
111In-PSI-CLNOD3
MN-Ex10-Cy5.5 Preclinical studies (in vitro and in vivo in mice) [42]
Np647–ExCys1 Preclinical studies (in vitro and in vivo in mice) [72]
E4K12-Fl
E4X12-VT750
Preclinical studies (in vitro and in vivo in mice) [68, 70]
64Cu-E4-Fl Preclinical studies (in vitro and in vivo in mice) [73]
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specific accumulation in β-cells. The fluorophore used in that
study, however, did not have ideal properties, as the emission
at 680 nm has a low tissue penetration. A second-generation
probe developed in the same group utilized a fluorochrome
emitting at 750 nm that circumvented tissue autofluorescence
and increased tissue penetration. The accumulation also cor-
related with BCM in healthy and streptozotocin-induced dia-
betic mice and detected β-cells loss before diabetic symptoms
appeared (Fig. 8) [68, 70]. Intravital confocal microscopy,
however, is still an invasive method, and further studies are
necessary to determine if this probe can be used non-
invasively. A more recent study tested a bimodal PET/
fluorescence tracer based on exendin-4 labeled with 64Cu,
allowing both whole-body PET images and high-resolution
images of single islets. The PET images successfully visual-
ized the tumor in mouse xenografts, though, no in vivo fluo-
rescent images have been performed so far [73].
Kang et al. chose a different approach by developing the
novel small molecule PiY (Fig. 9), which after intravenous
administration specifically labeled β-cells in the pancreas in
both mice and rats. PiY also successfully distinguished be-
tween healthy and diabetic tissue, proving its feasibility for
β-cell imaging. The specificity does not extend to organs such
as lung or liver, although heart showed a higher uptake than
the pancreas. Cellular uptake of the probe does not affect islet
function and viability, which is important for longitudinal
studies. Some aspects of PiY are still not fully clear, such as
the molecular target of the probe, which has to be investigated
to understand the selective staining of the β-cells. Another
open question is if the probe is suitable for in vivo imaging
use as all imaging studies so far were performed on ex vivo
organ sections [48].
Conclusions and future perspectives
Non-invasive imaging of β-cells remains a challenge.
Even in the healthy pancreas, an organ with 100–150 g,
only a low number of β-cells are present, merely 1–2% of
the pancreas are β-cells, which in addition are located
close to intestinal organs that can accumulate potential
tracers and thus obstructing the specific signal [119]. So
far, many various approaches for different applications
have been tested. The most promising application is the
Fig. 7 Mn2+-enhanced MRI of
the pancreas (dashed lines). a, c
Diabetic patient. b, d
Normoglycemic patient. e Signal
enchantment was significantly
higher in normoglycemic patients
[47]
Fig. 8 In vivo fluorescent
microscopy of pancreatic islets in
a mouse. aWhite light image. b
Fluorescent image. c Combined
picture. Adapted from [70]
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visualization of insulinomas and β-cell hyperplasia. As
they usually consist of β-cell clusters, accumulation in
those foci is usually stronger, allowing specific localiza-
tion of those lesions. Several radiotracers, both for PET
and SPECT imaging, are currently being used in clinics.
18F-DOPA, [11C]-5-HTP, and various exendin-based
probes have been successfully tested so far [33, 34,
51, 98]. Additionally, most of the β-cell-specific probes
allow the assessment of transplanted islets [12, 14, 31,
113–116].
The accurate quantification of BCM via imaging,
however, remains elusive. Although several groups re-
ported changes in tracer uptake of a diabetic pancreas
as compared to healthy organs in animal models and
humans, several important factors have to be considered
[22, 67, 70]. First of all, the tracer has to be specific for
β-cells. Residual uptake in other islet cells or the exo-
crine pancreas can result in an overestimation of the
BCM [23, 89]. Secondly, the variability of BCM in
healthy patients is very high, meaning that longitudinal
measurements are necessary to observe changes in BCM
over a period of time [66, 67]. This, however, means that
the tracer has to be non-toxic and should not damage
either β-cells or other tissue. This potentially might be
a problem for Mn2+ as MRI contrast agent, because the
toxicity has not yet fully tested, and radiotracers that
accumulate in non-target tissues leading to a high radia-
tion burden for the patients. Lastly, PET and SPECT
display a partial volume effect if the signal derives from
an object that is smaller than the spatial resolution of the
scanner, which may lead to an underestimation of the
signal. Unfortunately, until now, none of the currently
available tracers or contrast agents have been able to
address all challenges.
The most promising target so far is the GLP-1R.
Various studies with derivatives of exendin, the lead
structure for GLP-1R ligands, proved that the peptide
can be modified with various moieties without altering
the biological properties. This emphasizes the versatility
of this peptide, which has been successfully used as a
probe for PET, SPECT, MRI, and optical imaging [43,
117, 120]. A recent study showing that exendin-4 can
be modified in various positions without losing the af-
finity to the receptor concludes that multiple moieties
might be attached to the peptide, allowing a wider va-
riety of tracers [69]. Such modifications might include
multiple chelators, allowing an increase of the specific
activity of the tracer or the conjugation of two different
functionalities, for instance, a radioactive moiety and an
optical dye. This might allow a preoperative assessment
of the lesions using PET as well as direct visualization
of the small foci during the surgery. A dual-imaging
probe for this approach, based on exendin-4, has recent-
ly been published, and it is an important step towards
new hybrid imaging techniques for use in the clinic
[73].
Probes containing optical dyes have a high poten-
tial for future application. Guided surgery can allow a
more precise identification of the lesions during the
operation and the high sensitivity of the fluorescent
probes al lows the visual ization of the smallest
lesions.
In conclusion, many different probes have been tested
for imaging of β-cells, however, each tracer and imag-
ing modalities have different drawbacks. The most
promising target so far is the GLP-1R, as it is specifi-
cally expressed on β-cells and exendin-4, a specific ag-
onist of the receptor that can be modified at various
positions without losing the biological properties. Thus,
it can be utilized to attach various functional groups for
different imaging modalities allowing a high degree of
flexibility for clinical use.
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